Low valuations, positive clinical trial data and clarity around drug pricing reform could help revive the sector’s beaten-down stocks.
Signs of recovery in biotech?
Signs of recovery in biotech?
Low valuations, positive clinical trial data and clarity around drug pricing reform could help revive the sector’s beaten-down stocks.
Jeanette Patela
Katalin Kallo
Maximilian N. Beeck
Signs of recovery in biotech?
Low valuations, positive clinical trial data and clarity around drug pricing reform could help revive the sector’s beaten-down stocks.
Front-end rates indicate riskier assets need a reality check
This year’s bond market stress is a warning sign to other asset classes and the real economy.
Front-end rates indicate riskier assets need a reality check
This year’s bond market stress is a warning sign to other asset classes and the real economy.
Front-end rates indicate riskier assets need a reality check
This year’s bond market stress is a warning sign to other asset classes and the real economy.
Front-end rates indicate riskier assets need a reality check
This year’s bond market stress is a warning sign to other asset classes and the real economy.